Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target

  1. Andrew Bier1,
  2. Irene Oviedo-Landaverde1,
  3. Jing Zhao1,
  4. Yael Mamane2,
  5. Mustapha Kandouz1 and
  6. Gerald Batist1
  1. 1Departments of Oncology and Experimental Medicine, Segal Cancer Centre and Lady Davis Institute for Medical Research, Jewish General Hospital, and 2Department of Biochemistry and McGill Cancer Centre, McGill University, Montreal, Quebec, Canada
  1. Requests for reprints: Gerald Batist, Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, 3755 Cote-Ste-Catherine Road, Montreal, Quebec, Canada H3T 1E2. Phone: 514-340-8222, ext. 5418; Fax: 514-340-8708. E-mail: gerald.batist{at}mcgill.ca

Abstract

Connexin43 (Cx43) is often deregulated in breast cancer tissue compared with normal adjacent tissue. Stable reexpression of Cx43 in cancer slows growth and renders the cells more sensitive to cytotoxic chemotherapeutics. Pseudogenes are often considered nonfunctional copies of DNA. The Cx43 pseudogene (ΨCx43) possesses all the features of an expressed gene and is exclusively transcribed in breast cancer cell lines and not in normal cells. ΨCx43 can be translated in vivo, and its protein exhibits growth-suppressive behavior similar to Cx43. We showed that ΨCx43 binds to the polyribosomes in breast cancer cells and that exogenous expression of ΨCx43 induces translational inhibition of Cx43. Furthermore, ΨCx43 is translated and binds more efficiently to the translational machinery than does Cx43 in an in vitro system. Following knockdown of ΨCx43 in breast cancer cells, we observed an increase in Cx43 RNA and protein. This results in increased cellular sensitivity to cytotoxic chemotherapy. Our results show that ΨCx43 acts as a posttranscriptional regulator of Cx43 in breast cancer cells, and that this represents an example of the regulation of genes by pseudogenes with potential therapeutic implications in cancer. [Mol Cancer Ther 2009;8(4):786–93]

Keywords

Footnotes

  • Grant support: Canadian Institutes of Health Research/National Cancer Institute of Canada and FRSQ Cancer Research Network.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Received October 3, 2008.
    • Revision received January 21, 2009.
    • Accepted January 26, 2009.
« Previous | Next Article »Table of Contents